DRW Securities’s Fate Therapeutics FATE Stock Holding History

DRW Securities’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-21,550	Closed	-$70.7K	–	619
2024 Q2	$70.7K	Buy	+21,550	New	+$94.3K	﹤0.01%	497

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

DRW Securities's FATE Position: Q3 2024 in Review

DRW Securities sold out of Fate Therapeutics (FATE) in Q3 2024, closing a stake of 21,550 shares — an estimated $70.7K sold.

DRW Securities first reported a position in FATE in Q2 2024 and held it in 1 quarter. The position peaked at $70.7K in Q2 2024. 164 funds tracked by Wall St. Rank hold FATE as of Q3 2024.

DRW Securities reported no remaining Fate Therapeutics position as of Q3 2024 after selling out during the quarter.
DRW Securities sold 21,550 Fate Therapeutics shares in Q3 2024, an estimated $70.7K.
DRW Securities first reported a position in Fate Therapeutics in Q2 2024 and held it in 1 quarter.
DRW Securities's Fate Therapeutics position peaked at $70.7K in Q2 2024.
164 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2024.

Based on DRW Securities's 13F filing for Q3 2024, filed 13 Nov 2024.